In May 2024, Members of the Tuberculosis (TB) Vaccine Accelerator Council requested the WHO Secretariat to establish working groups to accelerate the achievement of goals aligned to its mission.
The Finance and Access Working Group (F&A) was established in February 2025 to promote timely and equitable global access to affordably priced new TB vaccines. Since TB primarily impacts low- and middle-income countries and has limited market potential in high-income regions, a strategic approach to market shaping, access and financing is essential. The working group will therefore coordinate efforts across governments, partners, financing institutions, private sector, and civil society to propose strategic partnerships, financing and procurement mechanisms, and market access solutions, with a particular focus on speeding up vaccine availability and access for high TB-burden countries.
WHO has published a new report “Catalysing solutions for equitable global access and sustainable financing for novel tuberculosis vaccines for adults and adolescents.” This report was launched on 6 NOvember 2025 at a high-level event during the G20 Health Minister’s meeting “Together for a TB-free world: Financing and access solutions for novel TB vaccines,” where ministers of health and global and regional partners are discussing recommendations from the report and collaborative next steps across different stakeholders.
The report was developed by the WHO TB Vaccine Accelerator Finance and Access working group, co-led by WHO, Gavi and the Government of South Africa. The report sets out the working group’s shared vision for equitable access to novel TB vaccines and will advance a shared understanding of the current landscape and its possible evolution in the future. It identifies six urgently needed solutions to accelerate access and financing and highlights the roles of different stakeholders to support the implementation of these solutions.
Catalyzing solutions for equitable global access and sustainable financing for novel...
Publications
An investment case for new tuberculosis vaccines
This document summarizes the results of the WHO-commissioned full value proposition for new tuberculosis (TB) vaccines. The assessment was commissioned...
A Global Strategy for tuberculosis research and innovation
The Global Strategy for Tuberculosis Research and Innovation will support the efforts of governments and other stakeholders to accelerate TB research...
The document presents WHO preferences for new tuberculosis vaccines, driven by the high medical need for contribution to the fight against TB, in alignment...